about
European evidence based consensus on the diagnosis and management of Crohn's disease: special situationsEffects of environmental agents on the attainment of puberty: considerations when assessing exposure to environmental chemicals in the National Children's Study.Pomalidomide is nonteratogenic in chicken and zebrafish embryos and nonneurotoxic in vitroThalidomide induces limb defects by preventing angiogenic outgrowth during early limb formationThalidomide-induced teratogenesis: history and mechanismsThe spectra of clinical phenotypes in aplasia cutis congenita and terminal transverse limb defectsEpidemiological surveillance of birth defects compatible with thalidomide embryopathy in BrazilEpidemiology of isolated preaxial polydactyly type I: data from the Polish Registry of Congenital Malformations (PRCM).The epidemiology of anotia and microtia.Amelia, dextrocardia, asplenia, and congenital short bowel in deleted ring chromosome 4.Clinical teratology: identifying teratogenic risks in humans.Chemical 'Jekyll and Hyde's: small-molecule inhibitors of developmental signaling pathwaysNew case of bilateral upper limb amelia, facial clefts, and renal hypoplasia.The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations.Thalidomide, a current teratogen in South America.Teratogen-induced limb defects.Dermatologic and nondermatologic uses of thalidomide.In vivo screening and discovery of novel candidate thalidomide analogs in the zebrafish embryo and chicken embryo model systems.Thalidomide induces limb anomalies by PTEN stabilization, Akt suppression, and stimulation of caspase-dependent cell deathSociodemographic and hispanic acculturation factors and isolated anotia/microtiaNew Findings in eNOS gene and Thalidomide Embryopathy Suggest pre-transcriptional effect variants as susceptibility factors.Thalidomide and misoprostol: Ophthalmologic manifestations and associations both expected and unexpected.Proper Use of Inflammatory Bowel Disease Drugs during Pregnancy.Effectiveness of Risk Evaluation and Mitigation Strategies (REMS) for Lenalidomide and Thalidomide: Patient Comprehension and Knowledge Retention.Genetics of renal hypoplasia: insights into the mechanisms controlling nephron endowment.European evidenced-based consensus on reproduction in inflammatory bowel disease.The pathogenesis of atrial and atrioventricular septal defects with special emphasis on the role of the dorsal mesenchymal protrusion.Management of gastrointestinal and liver diseases during pregnancy.Amelia: A Case Report and Literature Review.Classification of microphthalmos and coloboma.Fetal amelia: a case report.Offspring of male and female parents with thalidomide embryopathy: birth defects and functional anomalies.How do we know if an exposure is actually teratogenic in humans?Redox stress and signaling during vertebrate embryonic development: Regulation and responses.Asymmetrical tetraphocomelia with radiohumeral synostosis.Drug use before and during pregnancy in Serbia.Robotic assisted radical prostatectomy for localised prostate cancer in thalidomide generation.CPS49-induced neurotoxicity does not cause limb patterning anomalies in developing chicken embryos.Thalidomide embryopathy: Follow-up of cases born between 1959 and 2010.The return of thalidomide: are birth defects surveillance systems ready?
P2860
Q22242050-1DCB0990-07B8-4CC9-AFDA-D327CA02297CQ24537337-2D602AC0-64AF-4DDE-AE13-88EAFCE838C6Q24634078-EF05BE3B-DD69-497B-B6C2-7D28B75F4B83Q24653215-0588E7C1-808D-4901-A00F-61F7F01693BBQ28085087-19E58852-9FCD-4FDC-93EB-8D471890E60FQ28252346-3E74D905-B4A3-42B4-84DF-E0A126206DB5Q28478928-64310D5E-FCC2-40D3-AEF3-2BBA30041FBEQ30590988-E35DE9A2-68A1-4BDD-94E3-5DC5FC9736ADQ33677865-E2266F50-F9D7-4387-848A-9ED0050FE585Q33677935-624B5C82-77EB-4F39-BCFC-6AC1F2BA2AD5Q33832749-7A08E6C3-A8B0-4659-B11A-EBD3064DE8FDQ33877283-AE652804-5499-4AC3-A7A8-64E505EB7DBCQ33896799-BFD4477A-3C1D-41DE-AB56-EA10E20D4052Q34152778-67F9A459-6A51-4F4D-BF93-F219560012BDQ34421312-002D6327-1363-4FD0-8088-E15952133B78Q34926892-0FEBABFB-B6FC-48D3-BA06-ED97992A6DF8Q35201057-EECEDA46-D230-4E5B-9B28-97A02D6B0322Q36001001-29EBBB28-3DDA-484C-ABFA-30CB8FA2DF60Q36421389-CED7D581-2AC6-41B7-8D93-F18C8330B866Q36446546-48EB29CE-42B4-42A5-A006-DB40AA0EAE4AQ36719295-CA5E252E-1820-4416-9EF6-1133CE1E350AQ37565355-B8B665FF-A7F6-4526-8FD7-05CEBF6E73F3Q37656466-FA5487B2-DB2A-4803-ADFE-44327F529A39Q37716838-B0FB2248-506C-4B06-AFB3-3696CF1B66FBQ37737537-3784C83B-39C2-4992-BDD2-063A4EC2CCF1Q37814564-36174A0D-68D5-4DC0-B68C-1676CDC941E7Q38019645-4456B201-642B-4E7C-A909-8B4F65DBAC3DQ38178818-4C16445F-299A-464B-A7B0-46205AC80F96Q38658934-14984A7A-D7EC-4E45-BDC4-18CAD44940B8Q40864641-59DA4DCE-E2C0-48ED-9BD4-367A12153B29Q41258247-6069AE55-55EA-4DE2-B5F3-FCE79F155DAFQ44124753-65E454CF-58FF-4255-8A56-9D865A0BD8BCQ44842468-F548E24E-B14B-428D-BB0E-BBA880ECD382Q46304317-97E2AFBA-2580-4C38-B199-0FFBDC53212CQ46610056-85186A8A-1013-4D39-843F-D80A8D51F362Q47440060-9C0549F7-A1D0-45E4-9430-FCE86AD143CAQ48165254-2E304A6E-A2CC-43D9-A333-9C5DD81FB54CQ48202079-AB860C3C-DCFA-4FB8-B095-56D7A7D0CC2DQ50908946-2EB0CA0F-A301-4193-932C-39633635796AQ52191299-0524AB90-C8F6-43C8-A15F-C7360AC69711
P2860
description
1992 nî lūn-bûn
@nan
1992 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
Recognition of thalidomide defects.
@ast
Recognition of thalidomide defects.
@en
type
label
Recognition of thalidomide defects.
@ast
Recognition of thalidomide defects.
@en
prefLabel
Recognition of thalidomide defects.
@ast
Recognition of thalidomide defects.
@en
P2860
P356
P1476
Recognition of thalidomide defects.
@en
P2093
Smithells RW
P2860
P304
P356
10.1136/JMG.29.10.716
P407
P577
1992-10-01T00:00:00Z